• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Bivalirudin not linked to adverse cardiovascular events: The MATRIX program

byMatthew Lin, MDandShaidah Deghan, MSc. MD
September 6, 2015
in Cardiology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI) who received either heparin or bivalirudin were not significantly different in either the rates of major adverse cardiovascular events and overall adverse clinical events.

2. Use of bivalirudin in patients with ACS requiring PCI yielded a significantly lower rate of any-cause death as well as cardiac death compared to patients receiving heparin. 

Evidence Rating Level: 1 (Excellent)  

Study Rundown: The use of unfractionated heparin versus bivalirudin with a glycoprotein IIb/IIIa inhibitor are two of the most common antithrombotic regimens used worldwide for patients with acute coronary syndrome. Existing literature has yet to produce a definitive answer as to which approach is superior with regards to reducing ischemic, bleeding or mixed adverse outcomes. This large multicenter study investigated whether bivalirudin is superior to unfractionated heparin and discretionary use of glycoprotein IIb/IIIa inhibitors. This study found no significant differences among patients with ACS, patients undergoing PCI for major adverse cardiovascular events as a composite of any-cause death, MI and stroke, and no difference between net adverse clinical events, when heparin or bivalirudin were used. A statistically significant lower rate of any-cause death and cardiac death was observed in the bivalirudin group compared to the heparin group. The study results are limited by the use of pre-PCI glycoprotein IIb/IIIa inhibitors in the heparin group per physician judgment, as well as the use of two different regiments for post-PCI bivalirudin infusion.

Click to read the study in NEJM

Relevant Reading: Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome

In-Depth [randomized controlled trial]: Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) was a multicenter, randomized, open-label trial. A total of 7213 patients with ACS requiring PCI were randomly assigned to receive either bivalirudin or unfractionated heparin with PCI. Participants included NSTEMI patients with worsening ischemia and associated risk factors for cardiac disease as well as STEMI patients presenting within a limited timeframe from symptom onset. Follow-up occurred at 30 days and information for only 7188 of the participants were available. Primary outcomes included composite death from any cause or causes secondary to stroke or MI. Additional primary outcomes included adverse clinical events including major bleeding unrelated to CABG. Secondary outcomes included individual components of composites from the primary outcomes. For primary outcomes, there was no significant difference in major adverse cardiovascular events between the bivalirudin versus heparin groups (RR = 0.94; 95% [CI] = 0.81-1.09; p=0.44). Similarly, there was no difference in secondary outcomes for net adverse events between the two groups (RR = 0.89; 95% [CI] = 0.78-1.03; p=0.12). However, the rate of death from any cause was significantly lower in the bivalirudin group (RR=0.71, 95% [CI] = 0.51-0.99, p=0.04) as was the rate of death from cardiac causes (RR= 0.68; 95% [CI] = 0.48-0.97; p=0.03). This lower rate of death was associated with lower rates of bleeding in the bivalirudin group. The trial included two different regiments of post-PCI bivalirudin infusion in the bivalirudin group and for discretionary use of glycoprotein IIb/IIIa inhibitors in the heparin group which were consistent with the standard of practice but made interpretation of the data difficult. 

RELATED REPORTS

Adverse outcomes are similar for patients undergoing percutaneous coronary intervention receiving heparin or bivalirudin

2 Minute Medicine Rewind October 28 – November 3, 2013

Bivalirudin during transport for primary PCI reduces major bleeding

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bivalirudin
Previous Post

Aspirin therapy linked to fewer cases of preeclampsia

Next Post

AAP supports mandatory influenza vaccination of health care providers

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Adverse outcomes are similar for patients undergoing percutaneous coronary intervention receiving heparin or bivalirudin

September 22, 2017
Patient transfers to trauma centers often unnecessary
Cardiology

2 Minute Medicine Rewind October 28 – November 3, 2013

November 4, 2013
Computer more accurate than clinical gestalt in predicting ACS
Cardiology

Bivalirudin during transport for primary PCI reduces major bleeding

November 1, 2013
Next Post
AAP supports mandatory influenza vaccination of health care providers

AAP supports mandatory influenza vaccination of health care providers

High schoolers use e-cigarettes to vaporize cannabis

Herpes zoster vaccine not cost-effective for 50 year-old adults

Herpes zoster vaccine not cost-effective for 50 year-old adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind May 22nd, 2022
  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.